-transparent.png){kind=logo}
The relative availability of the orally administered hydrophobic antimalarial alpha-(dibutylaminomethyl)-6,8-dichloro-2-(3',4'-dichlorophenyl)-4-quinolinemethanol (I) from two dosage forms was determined in beagle dogs. Compound I was soluble in oleic acid to the extent of 23.5% (w/w), and oleic acid was suitable for encapsulation in soft gelatin capsules. The availability of I formulated as its hydrochloride salt in a standard hard gelatin capsule formulation was significantly lower than that of I formulated in a soft gelatin capsule with oleic acid as the solvent. A 20% solution of I in oleic acid (soft gelatin capsules) maintained at 23 degrees provided 4% of the oleic acid ester of I iwithin 1 month. Further reaction, however, was not seen over 2 years.
V Stella, and
J Haslam, and
N Yata, and
H Okada, and
S Lindenbaum, and
T Higuchi
January 1976,
Bollettino della Societa italiana di cardiologia,
V Stella, and
J Haslam, and
N Yata, and
H Okada, and
S Lindenbaum, and
T Higuchi
June 1982,
MMW, Munchener medizinische Wochenschrift,
V Stella, and
J Haslam, and
N Yata, and
H Okada, and
S Lindenbaum, and
T Higuchi
March 2012,
Journal of pharmacy & bioallied sciences,
V Stella, and
J Haslam, and
N Yata, and
H Okada, and
S Lindenbaum, and
T Higuchi
April 2007,
Journal of acquired immune deficiency syndromes (1999),
V Stella, and
J Haslam, and
N Yata, and
H Okada, and
S Lindenbaum, and
T Higuchi
April 1987,
British dental journal,
V Stella, and
J Haslam, and
N Yata, and
H Okada, and
S Lindenbaum, and
T Higuchi
March 2012,
Journal of pharmacy & bioallied sciences,
V Stella, and
J Haslam, and
N Yata, and
H Okada, and
S Lindenbaum, and
T Higuchi
March 1976,
Journal of pharmaceutical sciences,
V Stella, and
J Haslam, and
N Yata, and
H Okada, and
S Lindenbaum, and
T Higuchi
January 1976,
Bollettino della Societa italiana di cardiologia,
V Stella, and
J Haslam, and
N Yata, and
H Okada, and
S Lindenbaum, and
T Higuchi
February 2009,
Journal of clinical pharmacology,
V Stella, and
J Haslam, and
N Yata, and
H Okada, and
S Lindenbaum, and
T Higuchi
August 2002,
Clinical therapeutics,
